# VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

> **NCT05715125** · PHASE2 · TERMINATED · sponsor: **Ventyx Biosciences, Inc** · enrollment: 205 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Dose A VTX958
- **DRUG:** Dose B VTX958
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05715125
- **Lead sponsor:** Ventyx Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-31
- **Primary completion:** 2024-01-02
- **Final completion:** 2024-01-02
- **Target enrollment:** 205 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05715125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05715125, "VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05715125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*